Study record
IMerge Phase 3: imetelstat (telomerase INHIBITOR) in lower-risk MDS (Platzbecker et al., 2024)
Human clinical-outcome RCT — disease population (telomerase inhibitor)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 2 — Human clinical-outcome RCT — disease population
Record
| Design | Randomized, double-blind, placebo-controlled Phase 3 trial (transfusion-independence outcome) |
| N | 289 |
| Registry | NCT02598661 |
| DOI | 10.1016/S0140-6736(23)01724-5 |
| Citation status | doi verified via Crossref 2026-07-12 (Lancet 2024;403(10423):249-260, Platzbecker, Santini, Fenaux, et al., 'Imetelstat in patients with lower-risk myelodysplastic syndromes ... (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial'). NCT02598661 confirmed via ClinicalTrials.gov v2 API 2026-07-12 (Geron; randomized double-blind; enrolment 289; results posted 2025). FDA RYTELO approval June 2024: websearch-level. PMID not separately fetched (DOI is the confirmed primary identifier). |
Five-qualifier claim
| Species / population | Adults with transfusion-dependent, ESA relapsed/refractory IPSS low or intermediate-1 risk MDS — a DISEASE population (IMerge Phase 3, NCT02598661; enrolment 289). |
| Exposure, route, schedule | Intravenous imetelstat (a telomerase INHIBITOR) every 4 weeks. |
| Comparator / duration | Randomized, double-blind, placebo-controlled, multinational Phase 3. |
| Endpoint / numeric result | Higher rate of durable red-cell transfusion independence (≥8-week and ≥24-week) versus placebo, supporting FDA approval of RYTELO in June 2024. |
| What it did NOT establish | Cancer/hematology treatment via telomerase INHIBITION in a disease population — the OPPOSITE mechanistic direction from anti-aging 'activation'. Not an aging trial and not a lifespan outcome. |
Interventions
Primary reference
https://doi.org/10.1016/S0140-6736(23)01724-5
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.